
11 - 50 employees
🧬 Biotechnology
⚕️ Healthcare Insurance
💊 Pharmaceuticals
Biotechnology • Healthcare Insurance • Pharmaceuticals
Pulmovant is a company committed to transforming the lives of patients with pulmonary diseases by developing innovative therapies. Their lead product, mosliciguat, aims to provide a once-daily, inhaled treatment for pulmonary hypertension, distinguished by its novel sGC activation mechanism. With a singular focus on addressing the unique needs of patients suffering from pulmonary conditions, Pulmovant is engaged in extensive clinical trials to advance its pioneering treatment options.
🕒 May 5
Lead Biostatistics and Statistical Programming functions for Pulmovant’s innovative therapies. Providing strategic analysis and regulatory guidance for clinical development.
🕒 March 25
Director of Clinical Development at Pulmovant specializes in innovative therapies for pulmonary diseases. Responsible for clinical trial activities including design, execution, and oversight.
🕒 February 26
Director managing clinical development strategy and scientific publications at Pulmovant. Driving progress in innovative therapies for pulmonary diseases.